NASDAQ:BIIB
$53.85
(2/9 2:58PM)
+1.9%
| Open | $53.88 |
Mkt Cap | $15.3 Billion |
| High | $54.88 |
52Wk High | $55.37 |
| Low | $53.33 |
52Wk Low | $41.75 |
| Volume | 2.2 Million |
Avg Vol 10D | 2.7 Million |
Ockham's Rating/Recommendation Summary
Rating specific information requires Premium Access.
Buy Now
or
Learn More about Ockham's Features and Services.
BIIB Revenue
As a value investing shop, we are interested in seeing how BIIB's revenues measure up against past performances. One easily understandable way of doing that is to compare Price to Sales per share levels over a given time frame. Assuming it is available, Ockham prefers to look at ten years of history (for this stock there are 10 years of history available) and we weigh recent years more heavily. This allows us to find weighted average historical high and low Price to Sales ratios, which give us a better idea of the stock's current underlying value. Using this method, we have established a high range for Price to Sales of 12.38x and the low end of the range at 6.70x.
With respect to these historically rational metrics, notice that the current Price to Sales per share ratio for BIIB of 3.58x is well below its normal historic Price to Sales levels. At a price of $53.53, BIIB is 63% below where we would expect to see it. Clearly, this stock looks undervalued compared to historical levels, at least on a Price to Sales basis. This will positively affect our analysis because it is rare to find a stock this far below historical norms, and we would expect some price appreciation to bring this metric back towards a more normal range.
BIIB Cash Earnings
Looking at BIIB specifically in their Cash Earnings capabilities, Ockham views BIIB as significantly below their historical average multiples of Cash Earnings, as calculated by our proprietary analysis. It is incredibly important to understand that for BIIB, the current level of Cash Earnings compared to its historical levels helps identify where BIIB is in relation to what the investing community was willing to pay for this level of Cash Earnings in the past. With a historical high Cash Earnings per share ratio of 33.10 and a historical low Cash Earnings per share ratio of 17.94, an investor can relate where value becomes optimal.
So what does "significantly below" mean when we talk about Price to Cash Earnings numbers for BIIB? From the Ockham perspective, we are looking specifically at BIIB to see if the market is recognizing the huge disparity between BIIB's past stock price to Cash Earnings ratio to today's levels. At a difference of 55% below the average historical Price to Cash Earnings ratio, our view would be quite positive at this point. However, as with all metrics, we need to also take other factors into account when looking at BIIB. While we view better Cash Earnings metrics as very important, if the market is slow to identify this value, or if Cash Earnings were to fall from these levels, we would become more neutral in our stance.
BIIB Dividends
A strong dividend payment history is looked upon as a favorable characteristic on a company’s future and potentially can receive a positive Ockham rating. That being said, we don't require dividend payments for company's whose management has elected to forgo them entirely. As of the time of this report, our data provider does not have historical data for BIIB. Therefore, we are not utilizing the dividends portion in our study. So, we do not know whether BIIB currently pays a dividend at present or not, we have an "expected dividend" payment listed in key fundamentals but cannot varify it.
Earnings News Regarding Biogen IDEC, Incorporated Noted on Zero Hedge
Whenever a reliable source like Zero Hedge talks about earnings or news on earnings, we think it warrants bringing attention to it.
As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, BIIB has been less covered in the news compared to the rest of our universe of stocks. At Ockham, our stance is currently Greatly Undervalued, which means we believe that value investors will really be interested in this stock at the current price level. Crowd sentiment is neutral from the millions of opinions submitted through Motley Fool CAPS, which suggests most investors on their platform believe Biogen IDEC, Incorporated will perform just about the same as the index.
“… Earnings: AFG, AGCO, BIIB, CHD, CNC, CXW, DIS, EOG, IACI, QUIK, TAP, TCO, UBS, UDR, VMC, WMG, XL. RECENT RATING ACTIONSALLIANT TECHSYSTEMS INC (ATK)MGM MIRAGE (MGM)NCR CORP ... …”
News Breaking on Biogen IDEC, Incorporated on Imus In The Morning
Staying informed on the news is invaluable for investors, and RazorWire has captured a recently discussion on BIIB from Imus In The Morning.
Premium Content - please sign up for Ockham PREMIUM to gain full access and to see what Imus In The Morning said about BIOGEN IDEC, INC.
Learn About RazorWire?Finding Alpha: Seeking Alpha Wall St Breakfast Discusses BIIB
Will Biogen IDEC, Incorporated help you find that extra alpha your portfolio needs? Check what was said on Seeking Alpha Wall St Breakfast to see their take.
Crowd sentiment is neutral from the millions of opinions submitted through Motley Fool CAPS, which suggests most investors on their platform believe Biogen IDEC, Incorporated will perform just about the same as the index. At Ockham, our stance is currently Greatly Undervalued, which means we believe that value investors will really be interested in this stock at the current price level. As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, BIIB has been less covered in the news compared to the rest of our universe of stocks.
“… 10:00 Wholesale Trade 1:00 PM 3-Yr Note Auction 5:00 PM ABC Consumer Confidence Index Notable earnings before Tuesday's open: AGCO, AGU, ANR, BIIB, BJS, CAM, CE, CTSH, CVH, ... …”
News Developing on The Call for BIIB
Biogen IDEC, Incorporated is one of the thousands of companies that Ockham has news analytics on, and it was recently discussed on The Call.
The Motley Fool CAPS data suggests that investors believe Biogen IDEC, Incorporated will beat the market in the foreseeable future. As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, BIIB has been less covered in the news compared to the rest of our universe of stocks. At Ockham, our stance is currently Greatly Undervalued, which means we believe that value investors will really be interested in this stock at the current price level.
“… Pharmaceuticals reporter mike huckman with breaking news on BIOGEN IDEC. This is ticker symbol BIIB and the fda is putting a new warning on the label for the company's drug for ... …”
RazorWire has Detected News About BIIB on Fast Money
As always, the latest news on BIIB is available to Ockham clients through RazorWire, and it was mentioned recently on Fast Money.
This stock is trading for a price that is well below where we would expect given the fundamental strength, so we have a stance of Greatly Undervalued as of our most recent report. The Motley Fool CAPS crowd believes this stock will perform generally in line with the benchmark, or in other words the crowd is neutral. We noticed recently that in comparison to all other stocks we analyze in the news; BIIB has received less coverage from the financial media in business television and blogs.
“… BIOGEN, pfizer, glaxosmithkline all on deck to report innings, pete, your sector. > > pretty phenomenal. Look back to j&j and look forward to this week. …”
The Latest News for BIIB Was Just on Seeking Alpha Wall St Breakfast
As always, the latest news on BIIB is available to Ockham clients through RazorWire, and it was mentioned recently on Seeking Alpha Wall St Breakfast.
Crowd sentiment is neutral from the millions of opinions submitted through Motley Fool CAPS, which suggests most investors on their platform believe Biogen IDEC, Incorporated will perform just about the same as the index. At Ockham, our stance is currently Greatly Undervalued, which means we believe that value investors will really be interested in this stock at the current price level. As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, BIIB has been less covered in the news compared to the rest of our universe of stocks.
“… Proxy materials have reportedly been delivered to BIOGEN IDEC (BIIB) by Carl Icahn. A new proxy fight with BIOGEN would be Icahn's third in as many years as he aims for greater ... …”
A Discussion of BIIB's CEO Occurred on Squawk On The Street
Biogen IDEC, Incorporated's CEO is obviously vital to his company, so we believe any news covering him is worth knowing for investors.
As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, BIIB has been less covered in the news compared to the rest of our universe of stocks. At Ockham, our stance is currently Greatly Undervalued, which means we believe that value investors will really be interested in this stock at the current price level. Crowd sentiment is neutral from the millions of opinions submitted through Motley Fool CAPS, which suggests most investors on their platform believe Biogen IDEC, Incorporated will perform just about the same as the index.
“… Bio BIOGEN IDEC, ceo mullen will be stepping down. Talking about how sales talk starts to perk up. It's up 2% 3%. Google, nexus one unveiled a lot more chatter with apple and ... …”
BIIB News Mentioned on Squawk Box Recently
As always, the latest news on BIIB is available to Ockham clients through RazorWire, and it was mentioned recently on Squawk Box.
When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Biogen IDEC, Incorporated has actually sunk a bit in comparison to the others. Our sentiment indicator, provided through the Motley Fool CAPS survey, suggests that investors are neutral overall towards BIIB and think that it will generally perform in-line with the S&P 500. As for Ockham's rating, we currently have our most bullish stance of Greatly Undervalued on this stock as it is currently trading well below the price we would expect given the fundamentals.
“… let's start with BIOGEN idek, upgraded to neutral from underperform at bank of america. Ubs is talking about the retirement of james mullin. He is 51 years old. . …”
See Why Biogen IDEC, Incorporated News Was Discussed on Closing Bell
As always, the latest news on BIIB is available to Ockham clients through RazorWire, and it was mentioned recently on Closing Bell.
We noticed recently that in comparison to all other stocks we analyze in the news; BIIB has received less coverage from the financial media in business television and blogs. Crowd sentiment is leaning to the bearish side, according to the robust data set collected by the Motley Fool CAPS survey. This stock is trading for a price that is well below where we would expect given the fundamental strength, so we have a stance of Greatly Undervalued as of our most recent report.
“… He was with BIOGEN before it the stock's worth $15 billion. A little bit weaker in the after hours, but now it seems to be gaining strength. …”
RazorWire has Detected News About BIIB on Squawk On The Street
The latest news from business television and influential blogs is always available through Ockham's RazorWire, and this news is in relation to Biogen IDEC, Incorporated.
When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Biogen IDEC, Incorporated has actually sunk a bit in comparison to the others. As for Ockham's rating, we currently have our most bullish stance of Greatly Undervalued on this stock as it is currently trading well below the price we would expect given the fundamentals. Crowd sentiment is favorable on this stock, as measured by the Motley Fool CAPS survey.
“… So facet rejects BIOGEN's offer up 3. 5%. Jefferies upgrades t. Rowe price new newscorp also needham initiating a buy with a target of 18. It's currently 12. 44. …”